This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel
by Zacks Equity Research
Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.
LGNDPositive Net Change CTMXNegative Net Change AQSTNegative Net Change VRCANegative Net Change
biotechs medical
Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs
by Zacks Equity Research
Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.
BMYNegative Net Change EXELNegative Net Change ACADNegative Net Change TRDANegative Net Change
biotechnology biotechs pharmaceuticals
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
by Zacks Equity Research
Ultragenyx (RARE) reports preliminary full-year 2023 revenues, along with business updates, and shares 2024 revenue guidance.
PBYINegative Net Change RAREPositive Net Change ADMAPositive Net Change MREONegative Net Change
biotechnology biotechs medical pharmaceuticals
Amicus (FOLD) Issues Preliminary Revenue Results for FY23
by Zacks Equity Research
Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.
FOLDPositive Net Change SRPTPositive Net Change PBYINegative Net Change TRDANegative Net Change
biotechs
Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk
by Zacks Equity Research
Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.
RHHBYNegative Net Change NVONegative Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
Allogene (ALLO) Down 20% on Strategic Changes in Pipeline
by Zacks Equity Research
Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.
SRPTPositive Net Change CTMXNegative Net Change AQSTNegative Net Change ALLOPositive Net Change
biotechs medical
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
by Zacks Equity Research
Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.
DVAXPositive Net Change PCRXPositive Net Change ACADNegative Net Change TRDANegative Net Change
biotechnology biotechs pharmaceuticals
Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs
by Zacks Equity Research
Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.
AZNPositive Net Change NVONegative Net Change LLYNegative Net Change
biotechnology biotechs gene-therapy immuno-therapy medical pharmaceuticals
Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results
by Zacks Equity Research
Axsome (AXSM) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also provides regulatory updates on its pipeline candidates. Shares rise.
DVAXPositive Net Change JAZZPositive Net Change PBYINegative Net Change AXSMNegative Net Change
biotechs
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
by Ekta Bagri
REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
REGNNegative Net Change SRPTPositive Net Change BGNEPositive Net Change
biotechnology biotechs pharmaceuticals
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
by Zacks Equity Research
Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.
PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change IPHANegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study
by Zacks Equity Research
Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.
BMYNegative Net Change AGIONegative Net Change AQSTNegative Net Change
biotechs gene-therapy medical
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
by Zacks Equity Research
Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.
NVSNegative Net Change BMYNegative Net Change CORTNegative Net Change AGIONegative Net Change VYGRNegative Net Change
biotechnology biotechs pharmaceuticals
Here's Why You Should Invest in Adverum (ADVM) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.
NVONegative Net Change PBYINegative Net Change ADVMNegative Net Change AQSTNegative Net Change
biotechs
Ultragenyx (RARE) Posts Update From AS Study of GTX-102
by Zacks Equity Research
Ultragenyx (RARE) completes enrollment in the phase I/II study of GTX-102 for the treatment of pediatric patients with AS. Top-line data from the study is expected in the first half of 2024.
PBYINegative Net Change RAREPositive Net Change ADMAPositive Net Change ACADNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation
by Zacks Equity Research
Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.
BMYNegative Net Change MRKNegative Net Change MRTXPositive Net Change TRDANegative Net Change
biotechnology biotechs pharmaceuticals
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
by Zacks Equity Research
Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.
MRKNegative Net Change MRNANegative Net Change SRPTPositive Net Change CTMXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
by Zacks Equity Research
Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.
NVSNegative Net Change DVAXPositive Net Change VYGRNegative Net Change TRDANegative Net Change
biotechnology biotechs pharmaceuticals
C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why
by Zacks Equity Research
C4 Therapeutics (CCCC) shares surge on a licensing deal to develop degrader-antibody conjugates with Merck and positive data from CFT7455 studies.
DVAXPositive Net Change MRKNegative Net Change PBYINegative Net Change CCCCNegative Net Change
biotechs
BEAM Stock Rallies More Than 25% in 3 Months: What Next?
by Zacks Equity Research
BEAM is making good progress with its lead pipeline candidate, BEAM-101, which is being developed for treating sickle cell disease. Also, the recent restructuring efforts are expected to reduce costs.
DVAXPositive Net Change BEAMNegative Net Change PBYINegative Net Change TRDANegative Net Change
biotechs
Anavex (AVXL) Falls 35% on Mixed Rett Syndrome Study Results
by Zacks Equity Research
Anavex (AVXL) falls 35% on mixed results from the mid to late-stage study of 30 mg ANAVEX2-73 for the treatment of pediatric Rett Syndrome patients aged 5-17 years.
PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change AVXLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study
by Zacks Equity Research
Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.
PBYINegative Net Change ADMAPositive Net Change XENENegative Net Change
biotechnology biotechs medical pharmaceuticals
Top 5 Momentum Picks for January After a Fabulous 2023
by Nalak Das
We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.
REGNNegative Net Change SPLKPositive Net Change CASYNegative Net Change SHOPPositive Net Change BGNEPositive Net Change
biotechs internet retail
Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why
by Zacks Equity Research
Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.
VRTXPositive Net Change EDITNegative Net Change CRSPNegative Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.
PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change AXSMNegative Net Change
biotechnology biotechs medical pharmaceuticals